Current evidence suggests that H19 is overexpressed in prostate cancer, glioblastoma, and breast cancer and is associated with cancer progression (Bauderlique-Le Roy et al., 2015; Jiang et al., 2016; Peng F. et al., 2017). Here, H19 is linked to prostate cancer.